Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A.

Clin Cancer Res. 2012 Sep 1;18(17):4830-40. Epub 2012 Jul 3.

2.

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ.

Drug Metab Dispos. 2011 Oct;39(10):1873-82. doi: 10.1124/dmd.111.039164. Epub 2011 Jul 13.

3.

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ.

Clin Cancer Res. 2009 Nov 15;15(22):7085-91. doi: 10.1158/1078-0432.CCR-09-0822. Epub 2009 Nov 10.

4.

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK.

Cancer Res. 2007 Jul 1;67(13):6383-91.

5.

Development of C5a receptor antagonists. Differential loss of functional responses.

Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S, Fischer P, Rosen H, Mumford RA, Springer MS.

J Immunol. 1994 Nov 1;153(9):4200-5.

PMID:
7930622
6.

The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs.

DeMartino JA, Van Riper G, Siciliano SJ, Molineaux CJ, Konteatis ZD, Rosen H, Springer MS.

J Biol Chem. 1994 May 20;269(20):14446-50.

7.

Modulatory effect of endopeptidase inhibitors on bradykinin-induced contraction of rat uterus.

Schriefer JA, Molineaux CJ.

J Pharmacol Exp Ther. 1993 Aug;266(2):700-6.

PMID:
8394914
8.

Regulation of beta-endorphin secretion by corticotropin-releasing factor in the intact rat testis.

Eskeland NL, Molineaux CJ, Schachter BS.

Endocrinology. 1992 Mar;130(3):1173-9.

PMID:
1537283
9.

Inhibition of endopeptidase-24.15 decreases blood pressure in normotensive rats.

Genden EM, Molineaux CJ.

Hypertension. 1991 Sep;18(3):360-5.

10.

Endopeptidase-24.15 in rat hypothalamic/pituitary/gonadal axis.

Pierotti AR, Lasdun A, Ayala JM, Roberts JL, Molineaux CJ.

Mol Cell Endocrinol. 1991 Apr;76(1-3):95-103.

PMID:
1820981
11.
12.

Antinociceptive properties of inhibitors of endopeptidase 24.15.

Kest B, Orlowski M, Molineaux CJ, Bodnar RJ.

Int J Neurosci. 1991 Jan-Feb;56(1-4):141-9.

PMID:
1938129
13.
14.

Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone.

Lasdun A, Reznik S, Molineaux CJ, Orlowski M.

J Pharmacol Exp Ther. 1989 Nov;251(2):439-47.

PMID:
2681686
15.

Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo.

Molineaux CJ, Lasdun A, Michaud C, Orlowski M.

J Neurochem. 1988 Aug;51(2):624-33.

PMID:
3292705
16.

Substrate-related potent inhibitors of brain metalloendopeptidase.

Orlowski M, Michaud C, Molineaux CJ.

Biochemistry. 1988 Jan 26;27(2):597-602.

PMID:
3162384
17.

Response of rat pituitary anterior lobe prodynorphin products to changes in gonadal steroid environment.

Molineaux CJ, Hassen AH, Rosenberger JG, Cox BM.

Endocrinology. 1986 Nov;119(5):2297-305.

PMID:
2876888
18.

Hemorrhagic shock and the central vasopressin and opioid peptide system of rats.

Feuerstein G, Molineaux CJ, Rosenberger JG, Zerbe RL, Cox BM, Faden AI.

Am J Physiol. 1985 Sep;249(3 Pt 1):E244-50.

PMID:
2863984
19.

Increased dynorphin immunoreactivity in spinal cord after traumatic injury.

Faden AI, Molineaux CJ, Rosenberger JG, Jacobs TP, Cox BM.

Regul Pept. 1985 May;11(1):35-41.

PMID:
2861626
20.

Endogenous opioid immunoreactivity in rat spinal cord following traumatic injury.

Faden AI, Molineaux CJ, Rosenberger JG, Jacobs TP, Cox BM.

Ann Neurol. 1985 Apr;17(4):386-90.

PMID:
2860844
21.

Effects of traumatic injury on dynorphin immunoreactivity in spinal cord.

Cox BM, Molineaux CJ, Jacobs TP, Rosenberger JG, Faden AI.

Neuropeptides. 1985 Feb;5(4-6):571-4.

PMID:
2860614
22.

Subcellular distribution of opioid peptides in rat hypothalamus and pituitary.

Molineaux CJ, Rosenberger JG, Cox BM.

J Neurochem. 1984 Dec;43(6):1616-23.

PMID:
6149267
23.

Effect of hemorrhage on vasopressin, dynorphin A, and leu5-enkephalin in the hypothalamo-pituitary system of the rat.

Feuerstein G, Molineaux CJ, Rosenberger JG, Zerbe RL, Cox BM, Faden AI.

Clin Exp Hypertens A. 1984;6(10-11):1973-6. No abstract available.

PMID:
6152409
24.

Dynorphin-A-(1-8) is contained within vasopressin neurosecretory vesicles in rat pituitary.

Whitnall MH, Gainer H, Cox BM, Molineaux CJ.

Science. 1983 Dec 9;222(4628):1137-9.

PMID:
6648526
25.

Dynorphins and Leu-enkephalin in brain nuclei and pituitary of WKY and SHR rats.

Feuerstein G, Molineaux CJ, Rosenberger JG, Faden AI, Cox BM.

Peptides. 1983 Mar-Apr;4(2):225-9.

PMID:
6622288
26.

Distribution of immunoreactive dynorphin in discrete brain nuclei; comparison with vasopressin.

Molineaux CJ, Feuerstein G, Faden AL, Cox BM.

Neurosci Lett. 1982 Nov 30;33(2):179-84.

PMID:
6130498
27.
28.

Conversion of amoscanate to a mutagenic metabolite in gnotobiotic mice implanted with Streptococcus equinus.

Reddy BS, Batzinger RP, Molineaux CJ, Bueding E.

Antimicrob Agents Chemother. 1982 Oct;22(4):707-8.

29.

Mutagenic activation of an antischistosomal drug by enteric Streptococcus sps in vitro and in vivo.

Molineaux CJ, Batzinger RP, Schmidt W, Bueding E.

Teratog Carcinog Mutagen. 1980;1(2):129-39.

PMID:
6119805
30.

Protection from mutagenic effects of antischistosomal and other drugs.

Bueding E, Batzinger RP, Cha YN, Talalay P, Molineaux CJ.

Pharmacol Rev. 1978 Dec;30(4):547-54. Review. No abstract available.

PMID:
392546

Supplemental Content

Loading ...
Support Center